This study aimed to explore the association between glycemic variability (GV) and postoperative atrial fibrillation (POAF) incidence.
Methods
In this retrospective study, we included patients undergoing cardiac surgeries. GV was calculated as the coefficient of variation of blood glucose and categorized into tertiles based on its distribution. The primary endpoint was the incidence of POAF. Logistic regression and restricted cubic splines were used to assess the relationship between GV and POAF.
Results
5365 patients were included, with a median age of 68.3 years, and 25.5 % were female. 1056 (19.7 %) patients developed new-onset POAF. Compared with the low GV group, moderate GV group (odds ratio [OR], 1.82; 95 % confidence interval [CI]: 1.49–2.22) and high GV group (OR, 2.25; 95 % CI, 1.80–2.82) were significantly associated with a higher incidence of POAF. The area under the receiver operating characteristic curve of GV in predicting POAF incidence was 0.77 (95 % CI: 0.76–0.79). There is a threshold-based nonlinear relationship between GV and the incidence of POAF: when GV was < 24 %, the likelihood of POAF increases with higher GV, whereas when GV ≥ 24 %, further increases did not significantly affect the risk of POAF.
Conclusions
Increased GV is associated with higher incidence of POAF.
{"title":"Relationship between glycemic variability and the incidence of postoperative atrial fibrillation following cardiac Surgery: A retrospective study from MIMIC-IV database","authors":"Zeming Zhou , Haorui Zhang , Yuanrui Gu , Ke Zhang , Chenxi Ouyang","doi":"10.1016/j.diabres.2024.111978","DOIUrl":"10.1016/j.diabres.2024.111978","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to explore the association between glycemic variability (GV) and postoperative atrial fibrillation (POAF) incidence.</div></div><div><h3>Methods</h3><div>In this retrospective study, we included patients undergoing cardiac surgeries. GV was calculated as the coefficient of variation of blood glucose and categorized into tertiles based on its distribution. The primary endpoint was the incidence of POAF. Logistic regression and restricted cubic splines were used to assess the relationship between GV and POAF.</div></div><div><h3>Results</h3><div>5365 patients were included, with a median age of 68.3 years, and 25.5 % were female. 1056 (19.7 %) patients developed new-onset POAF. Compared with the low GV group, moderate GV group (odds ratio [OR], 1.82; 95 % confidence interval [CI]: 1.49–2.22) and high GV group (OR, 2.25; 95 % CI, 1.80–2.82) were significantly associated with a higher incidence of POAF. The area under the receiver operating characteristic curve of GV in predicting POAF incidence was 0.77 (95 % CI: 0.76–0.79). There is a threshold-based nonlinear relationship between GV and the incidence of POAF: when GV was < 24 %, the likelihood of POAF increases with higher GV, whereas when GV ≥ 24 %, further increases did not significantly affect the risk of POAF.</div></div><div><h3>Conclusions</h3><div>Increased GV is associated with higher incidence of POAF.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111978"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.diabres.2024.111938
Myungsoo Im , Jinmi Kim , Soree Ryang , Doohwa Kim , Wook Yi , Jeong Mi Kim , Minsoo Kim , Yeong Jin Kim , Young Jin Kim , Hyuk Kang , In Joo Kim , Ram Jagannathan , Stephanie T. Chung , Michael Bergman , Arthur S. Sherman , Sang Soo Kim , Joon Ha
Aims
Because one-hour post-load plasma glucose (1h-PG) ≥ 155 mg/dL (8.6 mmol/L) has been proposed as an early marker for future diabetes but lacks sufficient longitudinal confirmation of its risk, we aimed to evaluate the risk of T2D based on 1h-PG and track changes of insulin sensitivity and β-cell function over time by 1h-PG in a longitudinal cohort.
Methods
OGTTs were conducted every 2 years in the 10-year longitudinal Korean Genome Epidemiology study (n = 6144) with three groups characterized at baseline: Low 1h-PG (< 155 mg/dL) with Normal Glucose Tolerance (NGT), High 1h-PG (≥155 mg/dL) with NGT, and prediabetes (PreDM).
Results
T2D risk was higher in people with High 1h-PG with NGT and PreDM than those with Low 1h-PG with NGT. Baseline insulin sensitivity in Low 1h-PG as measured by the insulin sensitivity and secretion (ISS) model and Matsuda insulin sensitivity index (ISI) was higher than in High 1h-PG, which was comparable to PreDM. β-cell function as assessed by ISS and the insulinogenic index decreased from Low 1h-PG to High 1h-PG to PreDM. Over time, insulin sensitivity decreased in the three groups. Time from High 1h-PG to T2D was 0.9 years shorter than from Low 1h-PG. All participants passed the 1h-PG threshold for T2D (209 mg/dL, 11.6 mmol/L) first, and 74 % passed the 1h-PG threshold for impaired glucose tolerance (IGT; 155 mg/dL) first.
Conclusions
High 1h-PG NGT is an intermediate risk category between Low 1h-PG NGT and PreDM and may provide an opportunity for early intervention to prese rve ß-cell function.
{"title":"High one-hour plasma glucose is an intermediate risk state and an early predictor of type 2 diabetes in a longitudinal Korean cohort","authors":"Myungsoo Im , Jinmi Kim , Soree Ryang , Doohwa Kim , Wook Yi , Jeong Mi Kim , Minsoo Kim , Yeong Jin Kim , Young Jin Kim , Hyuk Kang , In Joo Kim , Ram Jagannathan , Stephanie T. Chung , Michael Bergman , Arthur S. Sherman , Sang Soo Kim , Joon Ha","doi":"10.1016/j.diabres.2024.111938","DOIUrl":"10.1016/j.diabres.2024.111938","url":null,"abstract":"<div><h3>Aims</h3><div>Because one-hour post-load plasma glucose (1h-PG) ≥ 155 mg/dL (8.6 mmol/L) has been proposed as an early marker for future diabetes but lacks sufficient longitudinal confirmation of its risk, we aimed to evaluate the risk of T2D based on 1h-PG and track changes of insulin sensitivity and β-cell function over time by 1h-PG in a longitudinal cohort.</div></div><div><h3>Methods</h3><div>OGTTs were conducted every 2 years in the 10-year longitudinal Korean Genome Epidemiology study (n = 6144) with three groups characterized at baseline: Low 1h-PG (< 155 mg/dL) with Normal Glucose Tolerance (NGT), High 1h-PG (≥155 mg/dL) with NGT, and prediabetes (PreDM).</div></div><div><h3>Results</h3><div>T2D risk was higher in people with High 1h-PG with NGT and PreDM than those with Low 1h-PG with NGT. Baseline insulin sensitivity in Low 1h-PG as measured by the insulin sensitivity and secretion (ISS) model and Matsuda insulin sensitivity index (ISI) was higher than in High 1h-PG, which was comparable to PreDM. β-cell function as assessed by ISS and the insulinogenic index decreased from Low 1h-PG to High 1h-PG to PreDM. Over time, insulin sensitivity decreased in the three groups. Time from High 1h-PG to T2D was 0.9 years shorter than from Low 1h-PG. All participants passed the 1h-PG threshold for T2D (209 mg/dL, 11.6 mmol/L) first, and 74 % passed the 1h-PG threshold for impaired glucose tolerance (IGT; 155 mg/dL) first.</div></div><div><h3>Conclusions</h3><div>High 1h-PG NGT is an intermediate risk category between Low 1h-PG NGT and PreDM and may provide an opportunity for early intervention to prese rve ß-cell function.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111938"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.diabres.2024.111945
Elena Gamarra , Pierpaolo Trimboli , Giovanni Careddu , Andrea Fazi , Valentina Turra , Ambra Morelli , Elena Cimino , Paolo Di Bartolo , Umberto Valentini , Matteo Bonomo
Background and aims
Scuba diving for people with diabetes was discouraged due to hypoglycemia risks. However, evolving guidelines now enable safe diving for people with diabetes. Among them, the Diabete Sommerso® safety protocol. This study aims to describe data from 20 years of DS activities and evaluate the performance of the protocol in avoiding metabolic complications.
Research design and methods
During DS camps, participants are trained to monitor glycemia before and immediately after diving, aiming for stable levels between 150–250 mg/dl. Since 2004, glycemic data from dives conducted with DS/independently by its members have been collected.
Results
DS issued diving licenses to 74 type 1 diabetic people. Data are available for 68: median age was 32 years (IQR 22 yrs), diabetes duration 18 years (IQR 16 yrs), HbA1c 7 % (IQR 1 %). 34 used insulin pumps, 43 continuous glucose monitoring. A total of 1179 dives were analyzed, showing a median reduction in glycemia of −38 mg/dl during dives (IQR 92 mg/dl, p < 0.0001). Post-dive hypoglycemia occurred in 23 cases, 45 % of which involved protocol non-adherence. Hypoglycemia prevalence was 1.7 % when the protocol was followed. No severe hypoglycemic episodes occoured during/after diving.
Conclusions
Data from 1179 dives indicate that, with adherence to the safety protocol, scuba diving is safe and poses no risk of severe hypoglycemia for people with type 1 diabetes.
{"title":"Performance of a safety protocol for scuba diving in people with type 1 diabetes: 20 years of “Diabete Sommerso®” experience","authors":"Elena Gamarra , Pierpaolo Trimboli , Giovanni Careddu , Andrea Fazi , Valentina Turra , Ambra Morelli , Elena Cimino , Paolo Di Bartolo , Umberto Valentini , Matteo Bonomo","doi":"10.1016/j.diabres.2024.111945","DOIUrl":"10.1016/j.diabres.2024.111945","url":null,"abstract":"<div><h3>Background and aims</h3><div>Scuba diving for people with diabetes was discouraged due to hypoglycemia risks. However, evolving guidelines now enable safe diving for people with diabetes. Among them, the Diabete Sommerso® safety protocol. This study aims to describe data from 20 years of DS activities and evaluate the performance of the protocol in avoiding metabolic complications.</div></div><div><h3>Research design and methods</h3><div>During DS camps, participants are trained to monitor glycemia before and immediately after diving, aiming for stable levels between 150–250 mg/dl. Since 2004, glycemic data from dives conducted with DS/independently by its members have been collected.</div></div><div><h3>Results</h3><div>DS issued diving licenses to 74 type 1 diabetic people. Data are available for 68: median age was 32 years (IQR 22 yrs), diabetes duration 18 years (IQR 16 yrs), HbA1c 7 % (IQR 1 %). 34 used insulin pumps, 43 continuous glucose monitoring. A total of 1179 dives were analyzed, showing a median reduction in glycemia of −38 mg/dl during dives (IQR 92 mg/dl, p < 0.0001). Post-dive hypoglycemia occurred in 23 cases, 45 % of which involved protocol non-adherence. Hypoglycemia prevalence was 1.7 % when the protocol was followed. No severe hypoglycemic episodes occoured during/after diving.</div></div><div><h3>Conclusions</h3><div>Data from 1179 dives indicate that, with adherence to the safety protocol, scuba diving is safe and poses no risk of severe hypoglycemia for people with type 1 diabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111945"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To assess the rates and predictors of resolution and relapse of metabolic-dysfunction associated steatotic liver disease (MASLD) in individuals undergoing sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB).
Methods
This observational prospective cohort study involved 1618 propensity score-matched participants (81.5% female) with concurrent MASLD and obesity who underwent SG or OAGB between 2013 and 2023.
Results
In the context of a maximum follow-up of four years with a median follow-up of 2.2 years (IQR: 1.0–3.3), the overall rates of MASLD resolution and relapse were 71.1 per 1000 person-month and 8.7 per 1000 person-month, respectively. These rates were comparable between the SG and OAGB groups. Significant resolution predictors were a lower percentage of hepatic steatosis, a higher percentage of 12-month excess weight loss (EWL%), and younger age. In contrast, an increased percentage of liver steatosis, a higher pre-operative (Pre-Op) fat mass percentage (FM%), and older age were significant predictors of relapse.
Conclusion
This study found no significant differences in MASLD resolution and relapse rates between SG and OAGB. Key factors influencing MASLD outcomes included the percentage of hepatic steatosis, 12-month EWL%, Pre-Op FM%, and age.
{"title":"The journey of MASLD: Tracking resolution, relapse, and predictive factors after sleeve gastrectomy and one-anastomosis gastric bypass, a propensity score-matched cohort study","authors":"Sara Sadeghi , Farhad Hosseinpanah , Alireza Khalaj , Maryam Mahdavi , Majid Valizadeh , Hamidreza Taheri , Maryam Barzin","doi":"10.1016/j.diabres.2024.111969","DOIUrl":"10.1016/j.diabres.2024.111969","url":null,"abstract":"<div><h3>Aims</h3><div>To assess the rates and predictors of resolution and relapse of metabolic-dysfunction associated steatotic liver disease (MASLD) in individuals undergoing sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB).</div></div><div><h3>Methods</h3><div>This observational prospective cohort study involved 1618 propensity score-matched participants (81.5% female) with concurrent MASLD and obesity who underwent SG or OAGB between 2013 and 2023.</div></div><div><h3>Results</h3><div>In the context of a maximum follow-up of four years with a median follow-up of 2.2 years (IQR: 1.0–3.3), the overall rates of MASLD resolution and relapse were 71.1 per 1000 person-month and 8.7 per 1000 person-month, respectively. These rates were comparable between the SG and OAGB groups. Significant resolution predictors were a lower percentage of hepatic steatosis, a higher percentage of 12-month excess weight loss (EWL%), and younger age. In contrast, an increased percentage of liver steatosis, a higher pre-operative (Pre-Op) fat mass percentage (FM%), and older age were significant predictors of relapse.</div></div><div><h3>Conclusion</h3><div>This study found no significant differences in MASLD resolution and relapse rates between SG and OAGB. Key factors influencing MASLD outcomes included the percentage of hepatic steatosis, 12-month EWL%, Pre-Op FM%, and age.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111969"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To investigate insulin resistance and pancreatic β-cell function in overweight or obese people under the same glucose tolerance conditions.
The subjects were categorized based on the results of the oral glucose tolerance test (OGTT) and the BMI classification criteria. Basal and postprandial glucose concentrations, insulin concentrations, pancreatic β-cell function (HOMA-β), the insulin resistance index (HOMA-IR), and the insulin early secretion index (ΔI30/ΔG30) were compared between the different weight groups.
Among individuals with similar glucose tolerances, those in the obese group presented higher HOMA-β, HOMA-IR, and ΔI30/ΔG30 values than did those in the normal weight and overweight groups. Additionally, in individuals with normal glucose tolerance and early diabetes, OGTT 1-h plasma glucose concentrations demonstrated a stronger correlation with early insulin secretion across different body weights.
When the same glucose-tolerant population was grouped by weight, OGTTs were significantly less different than IRTs. Therefore, integrating both tests is the optimal approach. In individuals with preobesity, there is an increase in pancreatic β-cell function to maintain normal blood glucose levels. As the disease progresses, obesity substantially increases insulin resistance, which acts as a disease-promoting factor. Furthermore, OGTT 1-h plasma glucose concentrations are strongly correlated with insulin secretion in normal or early diabetic populations.
{"title":"Exploring insulin resistance and pancreatic function in individuals with overweight and obesity: Insights from OGTTs and IRTs","authors":"Xiaoxuan Liu , Huimin Zhou , Yixian Liu , Jinhong Li, Huijing Luo, Qian He, Yanv Ren, Xiaofang Zhang, Zuoliang Dong","doi":"10.1016/j.diabres.2024.111972","DOIUrl":"10.1016/j.diabres.2024.111972","url":null,"abstract":"<div><div>To investigate insulin resistance and pancreatic β-cell function in overweight or obese people under the same glucose tolerance conditions.</div><div>The subjects were categorized based on the results of the oral glucose tolerance test (OGTT) and the BMI classification criteria. Basal and postprandial glucose concentrations, insulin concentrations, pancreatic β-cell function (HOMA-β), the insulin resistance index (HOMA-IR), and the insulin early secretion index (ΔI30/ΔG30) were compared between the different weight groups.</div><div>Among individuals with similar glucose tolerances, those in the obese group presented higher HOMA-β, HOMA-IR, and ΔI30/ΔG30 values than did those in the normal weight and overweight groups. Additionally, in individuals with normal glucose tolerance and early diabetes, OGTT 1-h plasma glucose concentrations demonstrated a stronger correlation with early insulin secretion across different body weights.</div><div>When the same glucose-tolerant population was grouped by weight, OGTTs were significantly less different than IRTs. Therefore, integrating both tests is the optimal approach. In individuals with preobesity, there is an increase in pancreatic β-cell function to maintain normal blood glucose levels. As the disease progresses, obesity substantially increases insulin resistance, which acts as a disease-promoting factor. Furthermore, OGTT 1-h plasma glucose concentrations are strongly correlated with insulin secretion in normal or early diabetic populations.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111972"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.diabres.2024.111974
Saad Khan, Fatima Naveed, Rizwan Ahmad, Ayesha Khan, Faraz Arshad
{"title":"Exploring the interplay between systolic blood pressure, cardiovascular disease, and diabetes: A call for further research","authors":"Saad Khan, Fatima Naveed, Rizwan Ahmad, Ayesha Khan, Faraz Arshad","doi":"10.1016/j.diabres.2024.111974","DOIUrl":"10.1016/j.diabres.2024.111974","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111974"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.diabres.2024.111944
{"title":"The road to achieving diabetes education in schools","authors":"","doi":"10.1016/j.diabres.2024.111944","DOIUrl":"10.1016/j.diabres.2024.111944","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111944"},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.diabres.2024.111925
Yi-Hsuan Lin , Chia-Hung Lin , Yu-Yao Huang , An-Shun Tai , Shih-Chen Fu , Szu-Tah Chen , Sheng-Hsuan Lin
{"title":"Corrigendum to “Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study” [Diabetes Res. Clin. Pract. 186 (2022) 109816]","authors":"Yi-Hsuan Lin , Chia-Hung Lin , Yu-Yao Huang , An-Shun Tai , Shih-Chen Fu , Szu-Tah Chen , Sheng-Hsuan Lin","doi":"10.1016/j.diabres.2024.111925","DOIUrl":"10.1016/j.diabres.2024.111925","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111925"},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.diabres.2024.111937
Joanna Y Gong , Agus Salim , Spiros Fourlanos , Dianna J Magliano , Jonathan E Shaw
Aims
We assessed the extent to which using large geographic regions to group ethnicities (ancestries or countries-of-birth) masked intra-regional variation in diabetes risk.
Methods
We performed a cross-sectional analysis of the 2021 Australian National Census, which included self-reported health data. Ethnicity-specific diabetes prevalence was age/sex-standardised to a reference population of all census respondents 20 years and above.
Results
There were 17.5 million adults included in this study. Within four geographical regions, there was two-four-fold intra-regional variation in diabetes risk. Diabetes prevalence among people reporting a single East Asian ancestry ranged from less than the Australian prevalence (Japanese 4.2%, Thai 6.1%) to twice the Australian prevalence (Filipino 12.6%). Among people reporting a single South/Central Asian ancestry, diabetes prevalence ranged from 7.3% (Armenian) to 18.4% (Bangladeshi). Among people reporting a single Middle Eastern/North African ancestry, diabetes prevalence values ranged from 5.4% (Jewish) to 12.3% (Iraqi). In Oceania, the diabetes prevalence in people of Australian Aboriginal, Fijian, Maori, Samoan and Tongan ancestry was greater than the Australian prevalence (17.5%, 12.3%, 10.0%, 16.3% and 17.4%, respectively versus 6.3%).
Conclusions
There was two-four-fold variation in diabetes prevalence between populations within four geographical regions. Aggregating ethnicity into large geographic regional groups may incorrectly estimate diabetes risk.
{"title":"The impact of ethnicity and its definition on diabetes prevalence: A national Australian whole-of-population study","authors":"Joanna Y Gong , Agus Salim , Spiros Fourlanos , Dianna J Magliano , Jonathan E Shaw","doi":"10.1016/j.diabres.2024.111937","DOIUrl":"10.1016/j.diabres.2024.111937","url":null,"abstract":"<div><h3>Aims</h3><div> <!-->We assessed the extent to which using large geographic regions to group ethnicities (ancestries or countries-of-birth) masked intra-regional variation in diabetes risk.</div></div><div><h3>Methods</h3><div>We performed a cross-sectional analysis of the 2021 Australian National Census, which included self-reported health data. Ethnicity-specific diabetes prevalence was age/sex-standardised to a reference population of all census respondents 20 years and above.</div></div><div><h3>Results</h3><div> <!-->There were 17.5 million adults included in this study. Within four geographical regions, there was<!--> <!-->two-four-fold intra-regional variation in diabetes risk. Diabetes prevalence among people reporting a single East Asian<!--> <!-->ancestry ranged from less than the Australian prevalence (Japanese 4.2%, Thai 6.1%) to twice the Australian prevalence (Filipino 12.6%). Among people<!--> <!-->reporting a single South/Central Asian<!--> <!-->ancestry, diabetes prevalence ranged from 7.3% (Armenian) to 18.4% (Bangladeshi). Among people reporting a single Middle Eastern/North African ancestry, diabetes prevalence values ranged<!--> <!-->from 5.4% (Jewish) to 12.3% (Iraqi). In Oceania, the diabetes prevalence in people of Australian Aboriginal, Fijian, Maori, Samoan and Tongan ancestry was greater than the Australian prevalence<!--> <!-->(17.5%, 12.3%, 10.0%, 16.3% and 17.4%, respectively versus 6.3%).</div></div><div><h3>Conclusions</h3><div> <!-->There was<!--> <!-->two-four-fold variation in diabetes prevalence between populations within four geographical regions. Aggregating ethnicity into large geographic regional groups may incorrectly estimate diabetes risk.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111937"},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.diabres.2024.111935
Sara Lena Lückmann , Antonia Förster , Stephanie Heinrich , Christian Buhtz , Gabriele Meyer , Rafael Mikolajczyk , Steffen Fleischer
Aims
Continuous glucose measurement (CGM) systems are increasingly utilised by people with diabetes mellitus (DM) and less is known about usage behaviour. Therefore, this study aims to analyse additionally utilisation of blood glucose measurement (BGM) for insurants who are using CGM.
Methods
The study used secondary data, health claims data from the AOK Saxony-Anhalt (Germany), from 2016 to 2021, analysing a sample of 52,296 individuals with insulin-requiring DM.
Results
Nearly all CGM users reduced their utilisation of BGM test strips. 2,306 persons with CGM long-time utilisation, about half showed a mean usage behaviour, nearly one third did not use test strips anymore, about 8 % stopped using CGM, 9 % were intense users. A high test strip utilisation beside CGM was associated with younger age, T1DM, a high number of test strip before starting CGM, no contact with a general practitioner, and no enrolment in a disease management program.
Conclusions
Great differences in reductions and usage behaviour was revealed between insurants. The results can be used to better identify and offer more tailored CGM to people with DM, and to better tailor CGM trainings.
{"title":"Utilisation of blood glucose test strips in insulin-requiring people with diabetes mellitus using continuous glucose monitoring in Saxony-Anhalt – Analysis of health insurance data","authors":"Sara Lena Lückmann , Antonia Förster , Stephanie Heinrich , Christian Buhtz , Gabriele Meyer , Rafael Mikolajczyk , Steffen Fleischer","doi":"10.1016/j.diabres.2024.111935","DOIUrl":"10.1016/j.diabres.2024.111935","url":null,"abstract":"<div><h3>Aims</h3><div>Continuous glucose measurement (CGM) systems are increasingly utilised by people with diabetes mellitus (DM) and less is known about usage behaviour. Therefore, this study aims to analyse additionally utilisation of blood glucose measurement (BGM) for insurants who are using CGM.</div></div><div><h3>Methods</h3><div>The study used secondary data, health claims data from the AOK Saxony-Anhalt (Germany), from 2016 to 2021, analysing a sample of 52,296 individuals with insulin-requiring DM.</div></div><div><h3>Results</h3><div>Nearly all CGM users reduced their utilisation of BGM test strips. 2,306 persons with CGM long-time utilisation, about half showed a mean usage behaviour, nearly one third did not use test strips anymore, about 8 % stopped using CGM, 9 % were intense users. A high test strip utilisation beside CGM was associated with younger age, T1DM, a high number of test strip before starting CGM, no contact with a general practitioner, and no enrolment in a disease management program.</div></div><div><h3>Conclusions</h3><div>Great differences in reductions and usage behaviour was revealed between insurants. The results can be used to better identify and offer more tailored CGM to people with DM, and to better tailor CGM trainings.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"218 ","pages":"Article 111935"},"PeriodicalIF":6.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号